Davy James, Managing Editor

Nanoscale treatment could potentially eliminate cancer cells without harming surrounding tissue.

Co-administration of amiodarone and Sovaldi or Harvoni also causes 9 patients to develop abnormally slow heartbeats, 3 requiring pacemakers.

Procedure allows acute liver failure patients to receive a transplant before their condition worsens.

Emerging technology could help patients make better decisions regarding whether to undergo aggressive prostate cancer treatment.

A look back at some of the top stories on Specialty Pharmacy Times from March 16-20.

Condition shares pathogenic mechanisms with rheumatoid arthritis.

Significant number of patients taking once daily oral therapy achieve clinical remission during a recent trial.

Discovery may lead to new treatment designs.

Experimental treatment blocks signaling protein.

Genetic variations on chromosome 15 dictate impact of NSAIDs.

Process produces protein with high blood clotting ability.

Risk of sudden onset menopause reduced by adding goserelin to chemotherapy regimen.

Report finds suppliers could spur investment through methods that include equipment leases or supplier-financed credit.

Treatment can selectively drop medication at the site of tumors.

Historical comparison shows advantage in virologic response for patients with genotype 1 hepatitis C.

Survivors of breast cancer more likely to develop aggressive form of thyroid cancer.

Study finds older patients and minorities less likely to receive treatment.

Scientists seek to create powerful defense system that will both attack the virus and prevent infection.

Study finds depression in African American cancer patients has gone under-recognized.